GI Pancreatic - Metastatic

IRB #19211
A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

IRB #21614
NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A Neoadjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.

IRB# 24549
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

IRB# 17751
Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

08 AUG 2022
https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
Quality Improvement Trials:

IRB # 22619: A Phase II Trial of Pre-operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy

IRB# 22413 Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result